Results
Par Drugs Board Approves FY26 Results Amid SEBI Restraint
Par Drugs board approved audited standalone financial results for Q4 and FY26 ended March 31, 2026, with an unmodified audit opinion.
SEBI has restrained the company's proposed business transfer arran
